ArticleNature medicine2024
An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score.
Abstract readMulticenter Study
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Burden of Potentially Undiagnosed Heart Failure With Preserved Ejection Fraction in Atrial Fibrillation and Effects of Catheter Ablation: Insights From CABANA.Journal of the American Heart Association · 2026Trial
- Assessing cardiovascular benefits of intensive blood pressure lowering in high-risk undiagnosed HFpEF patients.ESC heart failure · 2025Trial
- Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.Circulation · 2025 · on this mapTrial
- Longitudinal phenotyping of heart failure with preserved ejection fraction identifies early- and end-stage disease states.Open heart · 2026Article
- HFpEF-ABA Score for the Diagnosis and Prognosis of HFpEF in Outpatients With Type 2 Diabetes.JACC. Advances · 2026Article
- High-probability heart failure with preserved ejection fraction phenotype in atrial fibrillation patients undergoing ablation: insights from RECAP.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- HFpEF and MASLD: converging mechanisms and clinical implications.Nature reviews. Cardiology · 2026Review
- Heart Failure with Preserved Ejection Fraction in Women with Breast Cancer Prior to Cancer Treatment: Insights from a Cardio-Oncology Assessment.Journal of clinical medicine · 2026Article
- Understanding HFpEF Through Imaging: Strengths, Limitations, and Current State of the Art.JACC. Cardiovascular imaging · 2026Review
- Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.JACC. Heart failure · 2026Article
- The HFpEF-ABA score predicts adverse cardiac remodelling and incident heart failure: a UK biobank study.ESC heart failure · 2026Article
- Prognostic value of pretest probability of heart failure with preserved ejection fraction in patients with coronary artery disease: an insight from the CLIDAS-PCI database.Cardiovascular intervention and therapeutics · 2026Article
- Heart failure with preserved ejection fraction (HFpEF): Diagnosis and management for the general physician.Clinical medicine (London, England) · 2026Review
- Phenotypic Characterization of Unclassified Pulmonary Hypertension.Circulation. Heart failure · 2026Observational
- Metabolic Dysfunction-Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives.Reviews in cardiovascular medicine · 2026Review
- Implications of Potential Undiagnosed HFpEF on Symptomatic Response With Coronary Revascularization.JACC. Heart failure · 2026Article
- Article
- The diagnosis and subclassification of heart failure with preserved ejection fraction: a review.Heart failure reviews · 2026Review
- Heart failure with preserved ejection fraction for the clinician - highlights from the 5th annual Charleston HFpEF conference.Heart failure reviews · 2026Article
- Echocardiography in HIV Disease.Current cardiology reports · 2026Review
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Yogesh N V ReddyThe Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Rickey E CarterDepartment of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-0818-273X
Varun SundaramDepartment of Cardiology, Louis Stokes Cleveland Department of Veteran Affairs, Case Western Reserve University, Cleveland, OH, USA.
David M KayeDepartment of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.ORCID 0000-0003-4058-0372
M Louis HandokoDepartments of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences (ACS), Amsterdam, the Netherlands.ORCID 0000-0002-8942-7865
Ryan J TedfordDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0001-9045-7722
Mads J AndersenDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-9320-8227
Kavita SharmaDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Masaru ObokataDepartment of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
Frederik H VerbruggeFaculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.ORCID 0000-0003-0599-9290
Barry A BorlaugThe Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. borlaug.barry@mayo.edu.ORCID 0000-0001-9375-0596
Funding
Pulmonary Hypertension in Left Heart DiseaseR01HL162828 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2023 to 2026
$3.1MHL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4MMayo Clinic HeartShare Clinical CenterU01HL160226 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2021 to 2026
$1.8MPeripheral Limitations in Pulmonary Hypertension and Effects of Muscle TrainingK23HL164901 · NHLBI · MAYO CLINIC ROCHESTER · PI Yogesh Nellore Vilambi Reddy · 2023 to 2026
$671kNHLBI NIH HHS K23 HL164901NHLBI NIH HHS R01 HL128526NHLBI NIH HHS R01 HL162828NHLBI NIH HHS U01 HL160226U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) K23HL164901
Abstract
Heart failure with preserved ejection fraction (HFpEF) is under-recognized in clinical practice. Although a previously developed risk score, termed H
Indexed as
Heart FailureStroke VolumeAgedAged, 80 and overAtrial FibrillationBody Mass IndexCohort StudiesEchocardiographyFemaleHumansMaleMass ScreeningMiddle AgedRisk AssessmentRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.